NOVN.CH

117.02

+0.26%↑

NOVN.CH

117.02

+0.26%↑

NOVN.CH

117.02

+0.26%↑

NOVN.CH

117.02

+0.26%↑

NOVN.CH

117.02

+0.26%↑

Accueil・Liste d'Actions・Roche Holding AG

Roche Holding AG

Fermé

SecteurSoins de santé

330.4 0.85

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

330

Max

334.6

Chiffres clés
By Trading Economics
Revenu	1.8B 5.5B
Ventes	15B 31B
P/E Moyenne du Secteur	20.312 51.415
Rendement du dividende	3
Marge bénéficiaire	17.892
Employés	103,249
EBITDA	5.1B 12B

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	3.00% 2.34%

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-30B 259B
Ouverture précédente	329.55
Clôture précédente	330.4

Sentiment de l'Actualité

By Acuity

45%

55%

139 / 345 Classement par Healthcare

Roche Holding AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 mai 2026, 06:06 UTC

Acquisitions, Fusions, Rachats

Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

23 avr. 2026, 07:46 UTC

Résultats

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 avr. 2026, 05:40 UTC

Résultats

Roche Backs Full-Year View as Quarterly Sales Rise

9 mars 2026, 16:43 UTC

Principaux Mouvements du Marché

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 mars 2026, 15:44 UTC

Principaux Mouvements du Marché

Correction to Roche Shares Article

9 mars 2026, 09:51 UTC

Principaux Mouvements du Marché

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 mars 2026, 09:24 UTC

Principaux Mouvements du Marché

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

13 mai 2026, 10:20 UTC

Market Talk

Résultats

Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk

7 mai 2026, 05:53 UTC

Acquisitions, Fusions, Rachats

Correct: Roche to Buy PathAI for up to $1.05B

7 mai 2026, 05:07 UTC

Acquisitions, Fusions, Rachats

Roche: Acquisition Expected to Complete in 2H

7 mai 2026, 05:06 UTC

Acquisitions, Fusions, Rachats

Roche: Closing of Deal Subject to Customary Closing Conditions

7 mai 2026, 05:06 UTC

Acquisitions, Fusions, Rachats

Roche to Pay $750M Upfront, Milestone Payments of Up to $300M

7 mai 2026, 05:06 UTC

Acquisitions, Fusions, Rachats

Roche to Buy PathAI for up to $1.5B

7 mai 2026, 05:05 UTC

Acquisitions, Fusions, Rachats

Roche to Buy PathAI

6 mai 2026, 22:50 UTC

Résultats

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

27 avr. 2026, 09:54 UTC

Market Talk

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23 avr. 2026, 08:10 UTC

Market Talk

Résultats

Roche Reports In Line Sales Figures -- Market Talk

23 avr. 2026, 05:04 UTC

Résultats

Roche Backs 2026 View

23 avr. 2026, 05:04 UTC

Résultats

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 avr. 2026, 05:03 UTC

Résultats

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 avr. 2026, 05:02 UTC

Résultats

Roche 1Q Group Sales Up 6% at Constant Currency

23 avr. 2026, 05:02 UTC

Résultats

Analysts Saw Roche 1Q Sales at CHF14.73B

23 avr. 2026, 05:01 UTC

Résultats

Roche 1Q Sales CHF14.72B

10 avr. 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 avr. 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11 mars 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 mars 2026, 09:43 UTC

Actions en Tendance

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 mars 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 mars 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 mars 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

Comparaison

Variation de prix

Roche Holding AG prévision

Note du Consensus

By TipRanks

0 ratings

Achat

Maintien

Vente

Basé sur 0 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

139 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Autres valeurs du secteur

NOVN.CH

Novartis AG

117.02

↑ +0.26%

Roche Holding AG

Résumé

Variation du prix de l'action

Chiffres clés

Dividendes

Statistiques du Marché

Sentiment de l'Actualité

Roche Holding AG Graphique

Actualités Associées

Comparaison

Roche Holding AG prévision

Note du Consensus

Sentiment

Éléments financiers

À Propos Roche Holding AG

Autres valeurs du secteur